News
SPHRF
0.350
NaN%
--
UBS Group AG Withdraws as Substantial Shareholder in Starpharma
TipRanks · 3d ago
UBS exits substantial holder position in Starpharma
TipRanks · 09/15 08:28
Starpharma sets 2026 AGM date and flags board nomination deadline
TipRanks · 09/15 06:02
UBS Group Ceases to Be Substantial Shareholder in Starpharma
TipRanks · 08/31 09:24
Starpharma Highlights Patient-Focused Dendrimer Strategy in Annual Report
TipRanks · 08/26 01:04
Starpharma Boosts Revenue on Genentech Deal While Deepening R&D Spend
TipRanks · 08/26 00:17
UBS Group AG Drops Below Substantial Holding in Starpharma
TipRanks · 08/19 07:46
Starpharma Director Increases Stake Through Entitlement Offer
TipRanks · 08/13 11:12
Starpharma Director Increases Indirect Shareholding via Entitlement Offer
TipRanks · 08/13 11:12
Starpharma raises $32 million in heavily supported entitlement offer to fund oncology pipeline
TipRanks · 08/11 00:01
Starpharma launches $32m entitlement offer to fund oncology pipeline
TipRanks · 07/23 06:39
Starpharma outlines underwritten entitlement offer to shareholders
TipRanks · 07/14 23:28
Starpharma launches $32m entitlement offer to fund dendrimer oncology pipeline
TipRanks · 07/14 23:27
Starpharma Advances DEP Radiopharmaceuticals and Strengthens Oncology Partnerships
TipRanks · 07/14 23:18
Starpharma Showcases DEP HER2 Cancer Program in Investor Webinar
TipRanks · 07/07 05:47
Starpharma Hits DEP® Milestone, Opens Licensing Path With Radiopharm
TipRanks · 07/02 23:47
Starpharma Wins FDA Backing for DEP HER2 Trial as Partnerships and Product Sales Advance
TipRanks · 04/29 00:48
Starpharma Secures FDA Backing for DEP HER2 First-in-Human Trial Pathway
TipRanks · 04/21 00:04
Starpharma Seeks ASX Quotation for Over 1 Million New Shares
TipRanks · 04/06 23:33
UBS Group Ceases to Be Substantial Shareholder in Starpharma
TipRanks · 03/12 02:39
More
Webull provides a variety of real-time SPHRF stock news. You can receive the latest news about Starpharma Holdings Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SPHRF
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.